Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Mar 5.
doi: 10.1002/cpt.70256. Online ahead of print.

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Antonio Tursi  1   2 , Andrea Pasta  3 , Walter Elisei  4 , Brigida Barberio  5 , Giammarco Mocci  6 , Giovanni Maconi  7 , Antonietta Gerarda Gravina  8 , Raffaele Pellegrino  8 , Giorgia Bodini  3 , Edoardo Vincenzo Savarino  5 , Alfredo Papa  2   9 ; Italian Network for Inflammatory Bowel Diseases (IN‐IBD)
Collaborators, Affiliations

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Antonio Tursi et al. Clin Pharmacol Ther. .

Abstract

We evaluated whether concomitant 5-aminosalicylic acid (5-ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included. Time to clinical remission was analyzed using interval-censored Cox models. Among the 633 patients treated with JAKi, 476 patients received 5-ASA, and 151 did not. Cumulative probability of remission at week 48 was similar with and without 5-ASA, at 81.3% and 77.0%, respectively. The adjusted hazard ratio for 5-ASA vs. no 5-ASA was 1.12 (95% CI 0.91-1.37, P = 0.519). We therefore found that concomitant 5-ASA did not significantly affect the time to clinical remission in UC patients treated with JAKi.

PubMed Disclaimer

References

    1. Faleck, D.M., Shmidt, E., Huang, R. et al. Effect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn's disease: a systematic review and pooled meta‐analysis. Clin. Gastroenterol. Hepatol. 19, 238–245 (2021).
    1. Gorelik, Y., Freilich, S., Gerassy‐Vainberg, S. et al. Antibiotic use differentially affects the risk of anti‐drug antibody formation during anti‐TNFalpha therapy in inflammatory bowel disease patients: a report from the epi‐IIRN. Gut 71, 287–295 (2022).
    1. Gorelik, Y. et al. Association of Antibiotic use with durability of biologic agents in inflammatory bowel disease: a report from the epi‐IIRN. J. Crohns Colitis 17, 1410–1417 (2023).
    1. Lu, T.X., Dapas, M., Lin, E., Peters, T. & Sakuraba, A. The influence of proton pump inhibitor therapy on the outcome of infliximab therapy in inflammatory bowel disease: a patient‐level meta‐analysis of randomised controlled studies. Gut 70, 2076–2084 (2021).
    1. Raine, T. et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J. Crohns Colitis 16, 2–17 (2022).

LinkOut - more resources